Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Sponsor

Immtech Pharmaceuticals, Inc (Industry)

Overall Status

Completed

CT.gov ID

NCT00803933

Collaborator

Bill and Melinda Gates Foundation (Other)

111

Enrollment

Locations

Arms

Duration (Months)

55.5

Patients Per Site

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Human African Trypanosomiasis or sleeping sickness has made a spectacular return during the last decade, and in many places the demand largely surpasses the capacities of the treatment centers. Treatment of the disease remains unsatisfactory. All currently used drugs must be administered parenterally, treatment is lengthy, and adverse drug reactions frequent. There are currently no drugs that are easily administered and have low toxicity, and might thus be used as tools to support disease control.

This study aims to compare the safety and efficacy of DB289, a new, orally administered dication prodrug to pentamidine i.m. injection for the treatment of first stage sleeping sickness. The project will be executed in the framework of an international consortium consisting of several partners from academia, industry and from the Democratic Republic of Congo Ministries of Health.

Condition or Disease	Intervention/Treatment	Phase
African Trypanosomiasis	Drug: DB289 Drug: Pentamidine	Phase 2

Study Design

Study Type:

Interventional

Actual Enrollment :

111 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

Study Start Date :

Feb 1, 2003

Actual Primary Completion Date :

Feb 1, 2004

Actual Study Completion Date :

Jun 1, 2005

Arms and Interventions

Arm	Intervention/Treatment
Experimental: DB289 Pafuramidine maleate (DB289), 100 mg BID orally	Drug: DB289 Pafuramidine maleate (DB289), 100 mg BID orally Other Names: pafuramidine maleate
Active Comparator: Pentamidine Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM	Drug: Pentamidine Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM

Arm

Intervention/Treatment

Experimental: DB289

Pafuramidine maleate (DB289), 100 mg BID orally

Drug: DB289

Pafuramidine maleate (DB289), 100 mg BID orally

Other Names:

pafuramidine maleate

Active Comparator: Pentamidine

Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM

Drug: Pentamidine

Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM

Outcome Measures

Primary Outcome Measures

The primary efficacy endpoint was the parasitological cure at 3 months after completion of treatment. [3 months]
The primary outcome measure for safety analysis was the rate of occurrence of Grade 3 or higher adverse events during the observation period. [12 day]

Secondary Outcome Measures

The secondary outcome measure was the incidence rate of adverse events (all Grades combined) during the 7- to 9-day observation period in Treatment Sequence 1 and during the 12-day observation period in Treatment Sequence 2. [12 day]
The number and percentage of subjects with parasitological cure, subjects with confirmed (parasitological) treatment failure, and subjects with suspected treatment failure at 6, 12, and 24 months after completion of treatment. [6, 12, 24 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

15 Years to 50 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

The patient has early stage T. b. gambiense infection i.e. parasitologically confirmed infection in the blood or lymph node aspirate and greater than or equal to 5 WBC mm-3 detected in the CSF by microscopic examination
Patient is 15 to 50 years old
Patient has a minimal weight of 35 kilograms
If the patient is female of child bearing potential (a women will be considered of non-child bearing potential only if she has been post menopausal for over 2 years or has had a hysterectomy):
she is not lactating,
she had a negative urine pregnancy test result within 24 hours prior to DB289 treatment and
she agrees to use a medically proven method of contraception (abstinence from sexual intercourse is an acceptable method) from the day of consent on until the end of the observation period (day 7).
Patient has understood and signed the Informed Consent. If the patient is minor, a legal guardian has signed the Informed Consent

Exclusion Criteria:

The patient has late stage T.b. gambiense infection i.e. presence of parasite in the CSF upon microscopic examination or a WBC count of > 5mm-1
Active clinically relevant medical conditions that in the Investigator opinion may jeopardize subject safety or interfere with participation in the study, including but not limited to: significant liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, infection including known HIV infection, CNS trauma or seizure disorders (A list of typical signs and symptoms is provided for guidance of the investigator in attachment 1)
Coma Score of less than 9 on the Glasgow Coma Scale (Appendix 8)
Withdrawal of consent at any time during the study
Any condition which compromises ability to communicate with the investigator as required for the completion of this study.
The subject has been previously treated for African Trypanosomiasis.
The subject has been previously enrolled in the study. -